Francesca Palandri
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola(IT)
Publications by Year
Research Areas
Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, Eosinophilic Disorders and Syndromes, Chronic Lymphocytic Leukemia Research, Acute Myeloid Leukemia Research
Most-Cited Works
- → Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance(2007)743 cited
- → A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis(2017)325 cited
- → Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study(2016)249 cited
- → Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia(2009)210 cited
- → Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib(2019)197 cited
- → Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study(2009)196 cited